Blue Wolf Capital Partners to Acquire Seven European Manufacturing and Development Facilities from Recipharm

03 April 2024 | Wednesday | News

Blue Wolf Capital Partners LLC (“Blue Wolf”), a leading middle market private equity firm specializing in healthcare and industrial sectors, has announced its commitment to acquire seven manufacturing and development facilities from Recipharm, a renowned contract development and manufacturing organization (“CDMO”) based in Stockholm, subject to regulatory clearances.
Image Source | Public Domain

Image Source | Public Domain



The facilities, located in Solna, Stängnäs, Höganäs, Karlskoga, and Uppsala OTC Development in Sweden, Pessac in France, and Parets in Spain, have been integral parts of Recipharm for over a decade. Specializing in the manufacturing and development of oral solid, semi-solid, and liquid dosage form pharmaceutical products, these sites serve a diverse clientele of over 120 customers worldwide, boasting a strong track record of quality and regulatory compliance.

Upon completion of the transaction, these facilities will form a new independent CDMO platform operating under a new corporate identity, to be disclosed post-acquisition. Blue Wolf aims to leverage these assets to enhance manufacturing capabilities and development services, ensuring the continued delivery of high-quality pharmaceuticals to patients globally.

“Blue Wolf is excited for the opportunity to build a new CDMO platform with these seven European assets serving as a cornerstone,” said Shashank Patel, Principal at Blue Wolf. “Partnering with the leadership and teams at these facilities, we look forward to continuing to deliver world-class manufacturing capabilities and development services to our partners in order to provide the highest quality pharmaceuticals to patients around the world.”

Greg Behar, CEO of Recipharm, expressed confidence in the acquisition, stating, “I am confident that Blue Wolf will continue to elevate service excellence and bolster the organization for the benefit of customers and patients.”

The transaction, expected to close in Q4 2024, is subject to customary regulatory approvals. Terms of the agreement were not disclosed.

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in